Pacritinib
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 160 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Kinase Inhibitor, JAK2 Inhibitor, CSF1R Inhibitor, IRAK 1 Inhibitor, FLT3 Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1849
- NCT Identifier
- NCT06303193
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.